Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

FED 2OTHER 1

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 78Prostatic Neoplasms, Castration-Resistant 3Neoplasm Metastasis 3Prostatic Diseases 2Neoplasms 2Genital Diseases, Male 2Urogenital Neoplasms 1Stage II Prostate Adenocarcinoma 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostate Cancer With ≤10 Bone Metastases 1Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Patient Preference 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms by Site 1Neoadjuvant Therapy 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castrate-sensitive Prostate Cancer 1Low Risk Prostate Cancer 1High-Risk and Oligometastatic Prostate Cancer 1High Risk Prostate Cancer 1Hematologic Neoplasms 1Genital Neoplasms, Male 1Castration Levels of Testosterone 1

Interventions

pembrolizumab 155Gemcitabine 139Capecitabine 121Paclitaxel 118Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 92Cisplatin 89Irinotecan 87Carboplatin 84Radiosurgery 83Cyclophosphamide 70Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × apalutamide × Clear all
NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting
464 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT03098836 2025-09-12

PANTHER

Duke University

Phase 2 Completed
93 enrolled 17 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT05422911 2022-06-21

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

James J. Peters Veterans Affairs Medical Center

Phase 2 Not yet recruiting
200 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡